Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor

Area of Science:

• Oncology
• Epigenetics
• Drug Discovery

Background:

• Epigenetic dysregulation is a key factor in cancer development.
• Histone deacetylases (HDACs) are recognized as significant anticancer targets.
• Existing HDAC inhibitors have drawbacks, necessitating the development of new agents.

Purpose of the Study:

• To synthesize and evaluate the anticancer properties of a novel HDAC inhibitor, SF5-SAHA.
• To compare the efficacy of SF5-SAHA with the clinically used compound vorinostat/SAHA.
• To elucidate the mechanism of action of SF5-SAHA.

Main Methods:

• Synthesis and in vitro testing of SF5-SAHA.
• Cell viability assays (IC50 determination) using prostate and liver cancer cell lines.
• Western blot analysis for target-specific HDAC inhibition.
• LDH-release assays to assess unspecific cytotoxicity.
• Reactive oxygen species (ROS) and caspase-3 activity assays.
• Antiangiogenic activity assessment using the CAM assay.

Main Results:

• SF5-SAHA exhibited strong inhibition of tumor cell growth, with IC50 values comparable to or lower than vorinostat.
• Western blot confirmed target-specific HDAC inhibition.
• No unspecific cytotoxic effects were detected.
• SF5-SAHA induced pro-apoptotic ROS formation and caspase-3 activity in cancer cell lines.
• Antiangiogenic effects were observed in the CAM assay.
• The pentafluorothio-substituent in SF5-SAHA enhanced antiproliferative activity.

Conclusions:

• SF5-SAHA demonstrates significant anticancer potential through multiple mechanisms, including HDAC inhibition, apoptosis induction, and antiangiogenesis.
• The novel compound shows improved efficacy compared to vorinostat, particularly due to the pentafluorothio-substituent.
• SF5-SAHA is a promising candidate for further development as an epigenetic anticancer drug.